SELECT semaglutide to improve outcomes in patients with obesity and cardiovascular disease, also without diabetes.
作者信息
Gajos Grzegorz
机构信息
Department of Coronary Artery Disease and Heart Failure, Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland.
St. John Paul II Hospital, Kraków, Poland.
出版信息
Cardiol J. 2024;31(5):782-783. doi: 10.5603/cj.102158. Epub 2024 Sep 17.
Abstract
摘要
相似文献
1
SELECT semaglutide to improve outcomes in patients with obesity and cardiovascular disease, also without diabetes.选择司美格鲁肽以改善肥胖和心血管疾病患者（包括无糖尿病患者）的治疗效果。
Cardiol J. 2024;31(5):782-783. doi: 10.5603/cj.102158. Epub 2024 Sep 17.
2
Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT.司美格鲁肽与超重或肥胖但无糖尿病的 SELECT 人群的基线 HbA1c 和 HbA1c 变化的心血管结局
Diabetes Care. 2024 Aug 1;47(8):1360-1369. doi: 10.2337/dc24-0764.
3
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.司美格鲁肽对比安慰剂在射血分数轻度降低或保留的心衰患者中的疗效：SELECT、FLOW、STEP-HFpEF 和 STEP-HFpEF DM 随机试验的汇总分析。
Lancet. 2024 Sep 7;404(10456):949-961. doi: 10.1016/S0140-6736(24)01643-X. Epub 2024 Aug 30.
4
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.司美格鲁肽在肥胖但无糖尿病患者中的心血管结局。
N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.
5
The cost-effectiveness of semaglutide in reducing cardiovascular risk among people with overweight and obesity and existing cardiovascular disease, but without diabetes.司美格鲁肽在降低超重和肥胖且患有心血管疾病但无糖尿病患者心血管风险方面的成本效益。
Eur Heart J Qual Care Clin Outcomes. 2025 Sep 12;11(6):857-867. doi: 10.1093/ehjqcco/qcae063.
6
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.司美格鲁肽在肥胖合并心力衰竭患者中的心血管结局：SELECT 试验的预先指定分析。
Lancet. 2024 Aug 24;404(10454):773-786. doi: 10.1016/S0140-6736(24)01498-3.
7
The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial.司美格鲁肽对死亡率及新冠病毒相关死亡的影响：SELECT试验分析
J Am Coll Cardiol. 2024 Oct 22;84(17):1632-1642. doi: 10.1016/j.jacc.2024.08.007. Epub 2024 Aug 30.
8
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design.司美格鲁肽对超重或肥胖患者心血管结局的影响（SELECT）：基本原理和设计。
Am Heart J. 2020 Nov;229:61-69. doi: 10.1016/j.ahj.2020.07.008. Epub 2020 Jul 17.
9
Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial.SELECT 试验中，超重或肥胖但无糖尿病的人群中司美格鲁肽对血糖回归和进展的影响。
Diabetes Care. 2024 Aug 1;47(8):1350-1359. doi: 10.2337/dc24-0491.
10
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.SELECT 试验中的司美格鲁肽在非糖尿病肥胖患者中的长期减肥效果。
Nat Med. 2024 Jul;30(7):2049-2057. doi: 10.1038/s41591-024-02996-7. Epub 2024 May 13.
引用本文的文献
1
Evaluating the benefits of the early use of GLP-1 receptor agonists.评估早期使用胰高血糖素样肽-1（GLP-1）受体激动剂的益处。
Lancet. 2025 Jan 18;405(10474):181-183. doi: 10.1016/S0140-6736(24)02255-4. Epub 2024 Nov 12.
本文引用的文献
1
Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT.司美格鲁肽与超重或肥胖但无糖尿病的 SELECT 人群的基线 HbA1c 和 HbA1c 变化的心血管结局
Diabetes Care. 2024 Aug 1;47(8):1360-1369. doi: 10.2337/dc24-0764.
2
Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial.SELECT 试验中，超重或肥胖但无糖尿病的人群中司美格鲁肽对血糖回归和进展的影响。
Diabetes Care. 2024 Aug 1;47(8):1350-1359. doi: 10.2337/dc24-0491.
3
Role of glucagon-like peptide-1 receptor agonists in the treatment of obesity, cardiovascular disease, and cerebrovascular disease.胰高血糖素样肽-1 受体激动剂在肥胖、心血管疾病和脑血管疾病治疗中的作用。
Pol Arch Intern Med. 2024 Feb 28;134(2). doi: 10.20452/pamw.16658. Epub 2024 Jan 9.
4
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.司美格鲁肽在肥胖但无糖尿病患者中的心血管结局。
N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.
5
Body mass index and waist circumference in patients with established coronary artery disease over a 20-year period.20年间确诊冠心病患者的体重指数和腰围
Cardiol J. 2023;30(1):150-152. doi: 10.5603/CJ.a2023.0001. Epub 2023 Jan 18.
6
Management of obesity in the times of climate change and COVID-19: an interdisciplinary expert consensus report.气候变化和 COVID-19 时代的肥胖管理：跨学科专家共识报告。
Pol Arch Intern Med. 2022 Mar 30;132(3). doi: 10.20452/pamw.16216. Epub 2022 Feb 11.
Zotero 插件